In line with this, Kovacks and colleagues have recently reproduced the same observations in patients with both estrogen receptor (ER) negative and ER + breast cancer and observed that the TAAR1 agonist cadaverine exerts a beneficial effect against the development of breast cancer in vivo through TAARs [119]. Here, EREG is linked to breast carcinoma.